patients with acute heart- and/or lung failure R57.0 J80 R65
Conditions
Interventions
Group 1: A blood sample from patients with ECMO/ECLS will be taken at several points in time before, during and after EMCO/ECLS therapy.
Sponsors
Universitätsherzzentrum Freiburg - Bad KrozingenAbteilung Kardiologie und Angiologie I
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients with ECMO/ECLS
Exclusion criteria
Exclusion criteria: hemato-oncological basic disease; severe anemia requiring transfusions (Hb < 7 g/dl)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| detection of changes in hemostasis and vascular inflammation using blood test (standardized laboratory methods and specialized analytical methods (e.g. FACS, PCR, protein analysis) in the laboratory of the study coordinator)) before, during and after ECMO/ECLS support | — |
Secondary
| Measure | Time frame |
|---|---|
| correlation of criteria 1) with survival | — |
Countries
Germany
Contacts
Public ContactPatrick Siegel
Universitätsklinikum FreiburgKlinik für Kardiologie und Angiologie
Outcome results
None listed